NCT00522145 is a Phase 2 clinical trial of XL647 in Carcinoma, Non-Small-Cell Lung, sponsored by Kadmon Corporation, LLC.

Who is sponsoring NCT00522145?

NCT00522145 is sponsored by Kadmon Corporation, LLC.

What drugs are being tested in NCT00522145?

Interventions in NCT00522145: XL647.

What condition does NCT00522145 study?

NCT00522145 studies Carcinoma, Non-Small-Cell Lung.

Is NCT00522145 still recruiting?

NCT00522145 is currently completed. Last updated 9 May 2022.

Last reviewed 2022-05-09 · How we verify

NCT00522145

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 2 Study of XL647 in Subjects With Non-Small Cell Lung Cancer Who Have Progressed After Responding to Treatment With Either Gefitinib or Erlotinib

Completed Phase 2 Last updated 9 May 2022

What this trial tests

Phase 2 trial testing XL647 in Carcinoma, Non-Small-Cell Lung in 41 participants. Completed in 1 February 2010.

Timeline

1 May 2007

Primary endpoint
1 October 2009

1 February 2010

Quick facts

Lead sponsor	Kadmon Corporation, LLC
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	41
Start date	1 May 2007
Primary completion	1 October 2009
Estimated completion	1 February 2010
Sites	10 locations across United States

Drugs / interventions tested

XL647 — full drug profile →

Conditions studied

Carcinoma, Non-Small-Cell Lung — all drugs for Carcinoma, Non-Small-Cell Lung →

Sponsor

Kadmon Corporation, LLC — full company profile →

Who can join

18 and older, any sex, with Carcinoma, Non-Small-Cell Lung. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Determine the best confirmed response rate
Time frame: Inclusion until disease progression

Sponsor's own description

The purpose of this study is to determine the best confirmed response rate of daily administration of the multiple receptor tyrosine kinase (RTK) inhibitor (including EGFR and VEGFR2) XL647 in subjects with NSCLC who have progressed after responding to treatment with either erlotinib or gefitinib.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
Nguyen KS, Kobayashi S, Costa DB. · · 2009 · cited 340× · PMID 19632948 · DOI 10.3816/clc.2009.n.039
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
Costa DB, Nguyen KS, Cho BC, Sequist LV, et al · · 2008 · cited 137× · PMID 18981003 · DOI 10.1158/1078-0432.ccr-08-1455

Verify or expand the search:

Other recruiting trials for Carcinoma, Non-Small-Cell Lung

Currently open trials in the same condition.

NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting
NCT07222566 — Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adu · Phase 3 · recruiting
NCT07230691 — A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-Wor · recruiting
NCT07509333 — MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients · NA · recruiting
NCT07180862 — A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants · Phase 1 · recruiting

Other Kadmon Corporation, LLC trials

Trials by the same sponsor.

NCT04735822 — A Phase I Study to Evaluate the Taste of Belumosudil Oral Suspensions & Assess Relative Bioavailability · EARLY_PHASE1 · completed
NCT03907540 — Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025 · Phase 1 · completed
NCT03530995 — Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers · Phase 1 · completed
NCT03096080 — A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Pol · Phase 1 · completed
NCT02852967 — A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Se · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00522145 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kadmon Corporation, LLC
Last refreshed: 9 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00522145.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing